L&C Bio Co

L&C Bio Co Acquisitions (Net)

The Acquisitions (Net) of L&C Bio Co (290650.KQ) as of Oct 17, 2026 is -16.60 B KRW. In the previous year, Acquisitions (Net) was 49.62 B KRW — a change of -133.45% (lower).

Acquisitions (Net)

-16.60 BKRW

YoY

-133.45%

Last updated:

Acquisitions (Net) of L&C Bio Co is 2024 -16.60 B KRW. Acquisitions (Net) of L&C Bio Co was 2023 49.62 B KRW. It decreases by -133.45% lower compared to the previous year.

The L&C Bio Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
-326.50 M KRW
Jan 1, 2018
-12.00 B KRW
Jan 1, 2019
-13.80 B KRW
Jan 1, 2020
3.88 B KRW
Jan 1, 2021
-9.06 B KRW
Jan 1, 2022
-45.93 B KRW
Jan 1, 2023
49.62 B KRW
Jan 1, 2024
-16.60 B KRW
The L&C Bio Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
-16.60 BKRW-133.45%
49.62 BKRW-208.03%
-45.93 BKRW+406.92%
-9.06 BKRW-333.62%
3.88 BKRW-128.09%
-13.80 BKRW+15.08%
-12.00 BKRW+3,574.18%
-326.50 MKRW-90.66%
-3.50 BKRW+1,877.43%
-176.80 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

L&C Bio Co Stock analysis

What does L&C Bio Co do? L&C Bio Co Ltd is a South Korean biotechnology company based in Seongnam, Gyeonggi-Do. The company went public on November 1, 2018, as indicated by its IPO date. It operates within the healthcare sector, specifically in the biotechnology industry. L&C Bio Co Ltd focuses on the development and commercialization of soft tissue allografts and medical devices. The company manufactures and sells human tissue transplant materials designed for tissue repair and filler applications. Additionally, it produces human tissue-based medical devices and cosmeceuticals. Its products are utilized across various medical fields, including vascular surgery, plastic surgery, and general surgery. The company's website is http://www.lncbio.co.kr/. L&C Bio Co Ltd is listed on the Korean stock market with the ticker symbol 290650.KQ and ISIN code KR7290650001. The company's primary business activities revolve around the production and distribution of tissue-based medical solutions, targeting both clinical and cosmetic applications. No additional details regarding founding year, key personnel, acquisitions, or specific product names beyond those mentioned are provided in the available information. L&C Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about L&C Bio Co stock

Acquisitions (Net) of L&C Bio Co is -16.60 B KRW in 2024.

Acquisitions (Net) of L&C Bio Co changed from 49.62 B KRW to -16.60 B KRW, representing a -133.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) L&C Bio Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s L&C Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — L&C Bio Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — L&C Bio Co